Genmab — Maj 2020
-
“Hovedformålet med børsnoteringen i USA er at styrke profilen af Genmab og gøre os mere interessante at følge af analytikere i USA, og komme selskabet på radaren hos de store fonde i USA. De er nødvendige for at opbygge selskabet fra et 13 mia. dollar selskab til et selskab, der er 30-40 mia. dollar værd. Det er ambitionen,” siger Jan van de Winkel, adm. direktør i Genmab. ????
-
-
-
Er der nogen der kan se hvem det er der køber alle de aktier for tiden?
-
After hitting big in multiple myeloma, J&J, Genmab now have a new 'breakthrough' in NSCLC to boast about https://endpts.com/the-jj-genmab-alliance-that-hit-big-in-multiple-myeloma-now-has-a-new-breakthrough-in-nsclc-to-boast/
-
Jeg spekulerer lidt i et overtagelses scenarie, og i den forbindelse vil det være interessant at se hvem det er der køber op
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind